Related Experiment Video

Updated: Aug 8, 2026

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin

H Kakuta1, K Sudoh, M Sasamata

  • 1Pharmacology Laboratory, Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co, Ltd, Tsukuba, Japan. kakuta@yamanouchi.co.jp

International Journal of Clinical Pharmacology Research
|May 4, 2005
PubMed

Insights

Telmisartan exhibits the strongest binding affinity to the angiotensin II type 1 (AT1) receptor among tested blockers. This suggests potential for longer-lasting blood pressure control and enhanced heart protection in hypertensive patients.

Area of Science:

  • Cardiovascular Pharmacology
  • Hypertension Research
  • Drug Discovery

Background:

  • The renin-angiotensin system (RAS) is crucial in cardiovascular disease development.
  • Blocking the RAS offers significant cardiovascular protection.
  • Understanding differences in angiotensin II type 1 (AT1) receptor blocker (ARB) binding affinity is important for treatment.

Purpose of the Study:

  • To compare the in vitro dissociation rates of various ARBs from the AT1 receptor.
  • To determine the relative binding affinities of different ARBs.
  • To elucidate the clinical implications of varying ARB binding affinities.

Main Methods:

  • In vitro assessment of ARB dissociation from human AT1 receptor-containing membranes.
  • Measurement of dissociation rate constants and half-lives for telmisartan, olmesartan, candesartan, valsartan, losartan, and EXP3174.
  • Analysis of time-dependent dissociation kinetics.

Main Results:

  • Telmisartan demonstrated the slowest dissociation rate (0.003248 min⁻¹) and longest half-life (213 min) from the AT1 receptor.
  • The binding affinity rank order was telmisartan > olmesartan > candesartan > EXP3174 ≥ valsartan ≥ losartan.
  • Significant variations in dissociation rates were observed among the tested ARBs.

Conclusions:

  • Telmisartan possesses the strongest binding affinity to the AT1 receptor among the evaluated ARBs.
  • This superior binding may translate to prolonged antihypertensive effects and enhanced cardioprotection.
  • Findings support telmisartan's potential for superior clinical outcomes in hypertension management.

More Related Videos

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Live Cell Imaging and 3D Analysis of Angiotensin Receptor Type 1a Trafficking in Transfected Human Embryonic Kidney Cells Using Confocal Microscopy09:51

Live Cell Imaging and 3D Analysis of Angiotensin Receptor Type 1a Trafficking in Transfected Human Embryonic Kidney Cells Using Confocal Microscopy

Published on: March 27, 2017

Related Concept Videos

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...